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A B S T R A C T
Introduction: Chryseobacterium gleum is commonly distributed in the environment. It can cause a wide
variety of infections in immunocompromised patients in hospital setting.
Case presentation: A 6 month old infant with nephrotic syndrome was admitted to the emergency room
for an acute onset of fever, difﬁculty breathing, cyanosis, and low oral intake. Cultures of endotracheal
tube specimens were positive for Chryseobacterium gleum which was conﬁrmed by ribosomal
sequencing. The organism was susceptible to trimethoprim-sulfamethoxazole, minocycline, and
levoﬂoxacin. The patient clinically improved on levoﬂoxacin treatment.
Conclusion: To the best of our knowledge, this is the ﬁrst case of pneumonia caused by Chryseobacterium
gleum in an infant with nephrotic syndrome. It is also the ﬁrst report of C. gleum causing respiratory tract
infection in Saudi Arabia.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Chryseobacterium species are widely distributed in the envi-
ronment. They cause infections in hospitalized patients with
underlying conditions including immunocompromised patients
[1–3]. Age (infants, elderly) and medical devices such as
mechanical ventilators or indwelling intravascular devices are
also common risk factors [1,4].
Chryseobacterium species, formerly known as Flavobacterium,
belong to the family of Flavobacteriaceae [5]. CDC group IIb
comprises Chryseobacterium indolgenes and C. gleum and other
strains [5]. They are aerobic, yellow pigmented on blood agar,
catalase positive, oxidase positive, non motile, non glucose
fermenting Gram negative bacilli on MacConkey agar. These
strains can be differentiated based on DNA sequencing, several
phenotypic testing, and MALDI-TOF MS [5,6].
Although less common than C. indolgenes,C. gleum has been
reported to cause wide variety of infections including respiratory
tract infections, urinary tract infections, pyonephrosis, septicemia,
meningitis, wound infections, and peritonitis [1,3,7–9]. Infections
caused byC. gleumhad been reported in several countries including
India,Hungary,Croatia,Qatar, andTaiwan[1,6–9].Chryseobacterium
spp are resistant to several antibiotics such as aminoglycosides,
chloramphenicol, tetracyclines, clindamycin, teicoplanin, and
erythromycin [1,10,11]. In addition, these strains chromosomally
encode classAcarbapenemases and class Bmetallo beta lactamases
which confer resistance to all b-lactams [12].
Case report
A 6 month old infant brought to the emergency room in the
King Fahad Specialist Hospital-Dammam, Saudi Arabiawith cough,
fever, difﬁculty breathing, sneezing, irritation, excessive crying,
decreased oral intake, and cyanosis. He had been diagnosed with
infantile nephrotic syndrome 5 months earlier. In his past medical
history, he had several episodes of septicemia caused mainly by
Pseudomonas aeruginosa. In addition, he was previously on
multiple courses of antibiotics including meropenem, ceftriaxone,
and vancomycin. He was intubated and ventilated. Blood speci-
mens revealed mild neutrophilia and elevated CRP. Blood culture
and urine culture were negative. Chest X rays revealed left sided
pleural effusion with left lower lobe opacities. Several respiratory
specimens from endotracheal tube (ETT) were submitted to the
microbiology laboratory for culture. Round yellow pigmented non
hemolytic colonies grew on blood agar plates. Gram stain revealed
Gram negative bacilli. The organism was catalase and oxidase
positive. Organism identiﬁcation and antimicrobial susceptibility* Corresponding author.
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testing were carried out using the Vitek 2 automatic system
(bioMerieux, Paris, France) according the manufacturer’s instruc-
tions. E. coli ATCC 25922 and Pseudomonas aeruginosa ATCC
27853 strains were used as controls for the antimicrobial
susceptibility testing. There are no Clinical and Laboratory
Standards Institute (CLSI) guidelines speciﬁc for Chryseobacterium
species. However, minimum inhibitory concentrations (MIC) and
breakpoints were determined according to the CLSI recommenda-
tion for other Non-Enterobacteriaceae. The organism was identi-
ﬁed as Chryseobacterium gleum and it was conﬁrmed using
API20NE kit and 16 S rRNA sequencing. The organismwas resistant
to ceftazidime (MIC64mg/mL), cefepime (MIC64mg/mL),
meropenem (MIC16mg/mL), piperacillin-tazobactam (MIC
128mg/mL), colistin (MIC8mg/mL), gentamicin (MIC16
mg/mL), and amikacin (MIC64mg/mL). It was intermediate to
imipenem (MIC=8mg/mL), ciproﬂoxacin (MIC=2mg/mL), and
tigecycline (MIC =4mg/mL). The organism was susceptible to
trimethoprim-sulfamethoxazole (MIC20mg/mL), minocycline
(MIC1mg/mL), and levoﬂoxacin (MIC =0.5mg/mL). In addition,
the isolate was resistant to vancomycin. Environmental samples
from the mechanical ventilator and the patient room did not grow
any Chryseobacterium isolate. Chryseobacterium was tested for the
presence of carbapenem resistant genes (OXA48, NDM1, IMP, VIM,
CTX-14, CTX-M15, and KPC) by multiplex PCR methodology using
ARM-D for b-Lactamase ID kit (Streck, Omaha, NE, USA) as
instructed by the manufacturer. Positive controls and an internal
control are included in the kit. In addition, molecular grade water
(Promega, WI, USA) was used as a negative control to detect
contamination. None of the tested genes was detected by PCR. The
patient improved on levoﬂoxacin for a period of 16days and
subsequent respiratory specimens did not grow C. gleum. Neither
trimethoprim-sulfamethoxazole nor minocycline was used since
they were not available in hospital at time of treatment.
Discussion
A case of pneumonia caused by C. gleum in an infant with
nephrotic syndrome is reported in this study. To the best of our
knowledge, this is the ﬁrst report of respiratory tract infection due
to C. gleum in Saudi Arabia. It is also the ﬁrst report of association
between Chryseobacterium infection and nephrotic syndrome. This
is a noteworthy case since Chryseobacterium species are ubiquitous
in nature, are not part of human ﬂora, and can cause infections in
hospitalized patients with underlying disease [1,2,4]. In addition,
they are resistant to chlorination and are found on wet services of
medical devices and water systems. Therefore, medical devices
such as humidiﬁers, intubation tubes, and ventilators are impor-
tant sources for nosocomial infections caused by Chryseobacterium
spp [1,13]. VAP incidence is estimated to be 10–25% in Saudi Arabia
and is associated with 25–50% mortality rates of these cases [14].
Environmental and mechanical ventilator samples did not grow
any C. gleum in this case. However, intubation is a well known risk
factor for VAP caused by Chryseobacterium. Therefore, it should be
considered in the differential diagnosis as a causing agent
whenever a VAP case is encountered.
Patients with nephrotic syndrome suffer from infections due to
the loss of proteins including immunoglobulins in urine [15]. This
may explain in part why the patient developed pneumonia and
previous multiple episodes of septicemia. This study suggests that
nephrotic syndrome can be a risk factor for C. gleum infections. C.
gleum has the ability of bioﬁlm formation which can play a
signiﬁcant role in the establishment of infections and resistance to
wide variety of antimicrobial agents [7].
The choice of antibiotic agent for treatment is not well
established since there are insufﬁcient data regarding the
minimum inhibitory concentration proﬁle. In addition, there are
no CLSI guidelines for Chryseobacterium [10,11]. According to
report from the SENTRYantimicrobial surveillance program (1997–
2001), Chryseobacterium represented 0.27% of the studied non
fermentative Gram-negative rods and 0.03% of all bacterial isolates
[10]. Trimethoprim-sulfamethoxazole and newer generations of
quinolones (levoﬂoxacin, garenoxacin, and gatiﬂoxacin) were the
most active agents against Chryseobacterium [10]. Our data
correlated with this study where C. gleum strain was susceptible
to levoﬂoxacin and trimethoprim-sulfamethoxazole. However,
resistance to piperacillin-tazobactam and susceptibility to mino-
cycline in our study contradict data reported in the SENTRY study
regarding these two antibiotics [10].
There are discrepant data regarding Chryseobacterium suscep-
tibility to vancomycin. Several reports suggested susceptibility of
Chryseobacterium to vancomycin while other reports revealed
resistance to vancomycin [1,4,13]. In this study, the organism was
resistant to vancomycin in vitro.
This report highlights the importance of Chryseobacterium
species as a causing agent of the wide variety of infections. In
addition, it emphasizes the signiﬁcance of establishing antimicro-
bial susceptibility testing guidelines for the genus
Chryseobacterium.
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